{"id":"peg-ifn-wb-rbv-for-24-weeks","safety":{"commonSideEffects":[{"rate":"50–80%","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10–15%","effect":"Anemia"},{"rate":"5–10%","effect":"Neutropenia"},{"rate":"5%","effect":"Thrombocytopenia"},{"rate":"10–20%","effect":"Depression / mood changes"},{"rate":"20–30%","effect":"Headache"},{"rate":"15–25%","effect":"Insomnia"},{"rate":"5–10%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylated interferon-alpha (Peg-IFN) is a long-acting immunomodulator that activates innate and adaptive immune responses against HCV, while ribavirin (RBV) is a nucleoside analog that directly inhibits viral RNA synthesis. The combination enhances viral suppression and increases sustained virological response rates. This 24-week regimen was a standard-of-care treatment for chronic hepatitis C, particularly in genotype 2/3 patients.","oneSentence":"Pegylated interferon alpha combined with weight-based ribavirin stimulates the immune system to inhibit hepatitis C virus replication and clearance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:13.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 2 and 3)"},{"name":"Chronic hepatitis C virus infection (select genotype 1 patients)"}]},"trialDetails":[{"nctId":"NCT00532701","phase":"PHASE4","title":"Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-11","conditions":"Chronic Hepatitis C","enrollment":880}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys plus Copegus"],"phase":"marketed","status":"active","brandName":"Peg-IFN + WB RBV for 24 weeks","genericName":"Peg-IFN + WB RBV for 24 weeks","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha combined with weight-based ribavirin stimulates the immune system to inhibit hepatitis C virus replication and clearance. Used for Chronic hepatitis C virus infection (genotype 2 and 3), Chronic hepatitis C virus infection (select genotype 1 patients).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}